Financings Of The Fortnight Puts On The Weight

It didn't take long for Vivus Inc. to digest the impact of acing its FDA advisory committee review on Feb. 22. One week later, it went to the public markets for a stock sale, which we describe below.

Meanwhile, Vivus' two main competitors, both of whom have had the FDA send their dishes back to the kitchen at one time or another, saw action as well. Arena Pharmaceuticals Inc. spiked briefly to $2.11 a share on Feb. 23 with about 8 times its typical trading volume, only to drop back down under $2. The firm also triggered a sale of 14.4 million shares to Azimuth Opportunity Ltd